Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521341 | 0.86 | NOTUM (0.48) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL8567308 | 0.85 | NAMPT (0.46) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL8567306 | 0.85 | NAMPT (0.46) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL8567303 | 0.85 | NAMPT (0.46) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL16385106 | 0.85 | NAMPT (0.46) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL6410947 | 0.84 | NAMPT (0.46) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL15521240 | 0.82 | NAMPT (0.44) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL16384801 | 0.81 | NAMPT (0.43) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL16353469 | 0.80 | NAMPT (0.42) | NAMPTKDM1ANOTUMMTNR1AMTNR1B | |
| SCHEMBL16353534 | 0.80 | NAMPT (0.42) | NAMPTKDM1ANOTUMMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137371-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-05-18 | — | — | US | disclosed |
| US-20170137371-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-05-18 | — | — | US | disclosed |
| US-20170137371-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-05-18 | — | — | US | disclosed |
| US-9598371-B2 | Arylalkylamine compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-03-21 | — | — | US | disclosed |
| US-9598371-B2 | Arylalkylamine compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-03-21 | — | — | US | disclosed |
| US-9598371-B2 | Arylalkylamine compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-03-21 | — | — | US | disclosed |
| US-20160075655-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-03-17 | — | — | US | disclosed |
| US-20160075655-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-03-17 | — | — | US | disclosed |
| US-9227919-B2 | Arylalkylamine compounds as calcium sensing receptor modulators | LUPIN LIMITED (IN) | 2016-01-05 | — | — | US | disclosed |
| US-9227919-B2 | Arylalkylamine compounds as calcium sensing receptor modulators | LUPIN LIMITED (IN) | 2016-01-05 | — | — | US | disclosed |
| US-9227919-B2 | Arylalkylamine compounds as calcium sensing receptor modulators | LUPIN LIMITED (IN) | 2016-01-05 | — | — | US | disclosed |
| US-20150239827-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2015-08-27 | — | — | US | disclosed |
| US-20150239827-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2015-08-27 | — | — | US | disclosed |
| US-20150239827-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2015-08-27 | — | — | US | disclosed |
| EP-2888225-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | Lupin Limited (IN) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014033604-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033604-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137371-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, ORAI1 | NAMPT 3418/4885KDM1A 2847/4885NOTUM 3307/4885 |
| US-20150239827-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, ORAI1 | NAMPT 3418/4885KDM1A 2847/4885NOTUM 3307/4885 |
| US-20160075655-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, ORAI1 | NAMPT 3418/4885KDM1A 2847/4885NOTUM 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.